Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article by International Business Times referenced an article published in a supplement to The American Journal of Managed Care® (AJMC®), titled “Economic Burden of Alzheimer Disease and Managed Care Considerations.” In assessing the financial burden of Alzheimer disease, researchers said that unless new treatments or cures are developed, current treatment costs of $305 billion per year will rise to more than $1 trillion by 2050.
A piece by The Week spotlighted a video interview published on AJMC.com, the website of AJMC®. The interview, “Dr William "Andy" Nish Debunks Common Reasons for Not Getting COVID-19 Vaccine,” discussed false beliefs about COVID-19 vaccination, and why there is no good reason not to get inoculated, especially as the Delta variant spreads.
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Biosimilars Could Help With Increasing Costs for AMD Therapies in Medicare
September 29th 2023Drug maker payments to ophthalmologists were associated with the choice of higher-cost therapies for age-related macular degeneration (AMD) that could increase Medicare costs, but biosimilars could help.
Read More
Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer
September 29th 2023The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Read More
2 Clarke Drive
Cranbury, NJ 08512